Joseph Fiore

2.5k total citations · 1 hit paper
23 papers, 1.7k citations indexed

About

Joseph Fiore is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Joseph Fiore has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Joseph Fiore's work include Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Joseph Fiore is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Joseph Fiore collaborates with scholars based in United States, Taiwan and Spain. Joseph Fiore's co-authors include Amita Patnaik, Shirish M. Gadgeel, Vassiliki A. Papadimitrakopoulou, James Chih‐Hsin Yang, Harry Raftopoulos, Lecia V. Sequist, Hossein Borghaei, Leena Gandhi, Shadia I. Jalal and Matthew A. Gubens and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Joseph Fiore

23 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

2016 1.1k citations Corey J. Langer, Shirish M. Gadgeel et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph Fiore United States	12	1.5k	1.0k	340	183	125	23	1.7k
D.-W. Kim South Korea	15	844 0.6×	775 0.7×	162 0.5×	202 1.1×	232 1.9×	53	1.2k
Julie E. Stein United States	12	658 0.4×	281 0.3×	275 0.8×	151 0.8×	211 1.7×	24	1.0k
Christoph Helwig Germany	18	1.2k 0.8×	277 0.3×	465 1.4×	100 0.5×	338 2.7×	53	1.4k
Christina M. Kochel United States	9	952 0.6×	319 0.3×	644 1.9×	84 0.5×	136 1.1×	15	1.2k
Nahomi Tokudome Japan	18	980 0.7×	422 0.4×	108 0.3×	374 2.0×	206 1.6×	52	1.2k
Ritesh Rathore United States	15	837 0.6×	242 0.2×	239 0.7×	113 0.6×	217 1.7×	44	1.0k
Juan J. Grau Spain	21	847 0.6×	615 0.6×	178 0.5×	81 0.4×	278 2.2×	60	1.7k
Mahsa Mohebtash United States	14	683 0.5×	286 0.3×	574 1.7×	67 0.4×	197 1.6×	31	978
Jonathan Villena‐Vargas United States	14	1.6k 1.1×	520 0.5×	622 1.8×	63 0.3×	394 3.2×	39	2.1k
Rongrui Liu China	12	513 0.3×	288 0.3×	116 0.3×	149 0.8×	121 1.0×	30	767

Countries citing papers authored by Joseph Fiore

Since Specialization

Citations

This map shows the geographic impact of Joseph Fiore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Fiore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Fiore more than expected).

Fields of papers citing papers by Joseph Fiore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Fiore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Fiore. The network helps show where Joseph Fiore may publish in the future.

Co-authorship network of co-authors of Joseph Fiore

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Fiore. A scholar is included among the top collaborators of Joseph Fiore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Fiore. Joseph Fiore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fiore, Joseph, Yoon Jin, Tycho Heimbach, et al.. (2025). Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants—a randomized, open-label, three-period, crossover study. Antimicrobial Agents and Chemotherapy. 69(3). e0143424–e0143424. 1 indexed citations

Waser, Nathalie, Melanie Quintana, Bernd Schweikert, et al.. (2024). Pathological response in resectable non–small cell lung cancer: a systematic literature review and meta-analysis. JNCI Cancer Spectrum. 8(3). 6 indexed citations

Castellanos, Emily, Joseph Fiore, Stephen J. Lane, et al.. (2023). Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study. Clinical Pharmacology & Therapeutics. 113(4). 867–877. 6 indexed citations

Nadler, Eric, Anupama Vasudevan, Nicholas J. Robert, et al.. (2023). Real-World Relationship of Early End Points to Survival End Points in Patients with Resectable Non-Small-Cell Lung Cancer. Future Oncology. 19(26). 1785–1801. 6 indexed citations

Deutsch, Julie S., Ashley Cimino‐Mathews, Elizabeth D. Thompson, et al.. (2022). LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816. Annals of Oncology. 33. S1415–S1416. 4 indexed citations

Forde, Patrick M., Jonathan Spicer, Shun Lü, et al.. (2021). Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Research. 81(13_Supplement). CT003–CT003. 65 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129. 169 indexed citations

Yang, James Chih‐Hsin, Shirish M. Gadgeel, Chien-Liang Wu, et al.. (2018). Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of Thoracic Oncology. 14(3). 553–559. 130 indexed citations

Gubens, Matthew A., Lecia V. Sequist, James Stevenson, et al.. (2018). Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 130. 59–66. 74 indexed citations

10.

Paz-Ares, L., László Urbán, Clarisse Audigier-Valette, et al.. (2018). P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S493–S493. 7 indexed citations

11.

Gentzler, Ryan D., Corey J. Langer, Hossein Borghaei, et al.. (2018). 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.. Journal of Clinical Oncology. 36(15_suppl). 9026–9026. 14 indexed citations

12.

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2017). MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G. Journal of Thoracic Oncology. 12(1). S391–S392. 1 indexed citations

13.

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2017). Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Annals of Oncology. 28. v636–v637. 19 indexed citations

14.

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2017). OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update. Journal of Thoracic Oncology. 12(11). S1791–S1791. 9 indexed citations

15.

Papadimitrakopoulou, Vassiliki A., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2017). First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.. Journal of Clinical Oncology. 35(15_suppl). 9094–9094. 15 indexed citations

16.

Langer, Corey J., Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, et al.. (2016). Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Annals of Oncology. 27. vi582–vi582. 8 indexed citations

17.

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2016). Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 17(11). 1497–1508. 1071 indexed citations breakdown →

18.

Mehrzad, Raman, et al.. (2015). Right-Sided Diverticulosis and Disparities from Left-Sided Diverticulosis in the Vietnamese Population Living in Boston, Mass., USA: A Retrospective Cohort Study. Medical Principles and Practice. 24(4). 355–361. 11 indexed citations

19.

Sachs, Stephen A. & Joseph Fiore. (2003). An overview of lung cancer. PubMed. 9(1). 1–25. 5 indexed citations

20.

Bender, M. A., et al.. (1988). Normal G2 chromosomal radiosensitivity and cell survival in the cancer family syndrome.. PubMed. 48(9). 2579–84. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact